Annexon Biosciences (NASDAQ:ANNX) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The company’s shares have skyrocketed by 289.29% over the past year and by 39.45% year-to-date. On April 16, Needham analyst Joseph Stringer assigned a Buy rating on Annexon Biosciences and set a price target of $11.00.
In March, Annexon president and chief executive officer Douglas Love highlighted progress in the company’s portfolio and announced key anticipated milestones. He said:
“Grounded in robust vonaprument Phase 2 ARCHER data and strong execution of the ongoing Phase 3 ARCHER II trial, we are on track to report topline pivotal data in the fourth quarter of this year. ARCHER II is the first study to evaluate visual preservation as the primary endpoint in patients with GA (Geographic Atrophy) and the first pivotal study with an aligned global regulatory path.”
Love said that the company has also filed for Marketing Authorization Application (MAA) in the EU for tanruprubart and is preparing for potential approval of the first targeted therapy for Guillain-Barré Syndrome (GBS). He added:
“We’re also focused on the ongoing US/EU FORWARD study which is designed to broaden experience across western geographies to support a planned U.S. Biologics License Application (BLA) submission in 2026. Lastly, we anticipate POC data for our first-in-kind classical complement oral inhibitor, ANX1502, in autoimmune disease this year. Overall, with a strengthened balance sheet and continued focus on our core priorities, we are well-positioned to deliver multiple near-term value-driving catalysts in the year ahead.”
Annexon Biosciences (NASDAQ:ANNX) is a biopharmaceutical company advancing the next-generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. The firm’s targeted therapies are designed to stop classical complement-driven neuroinflammation at its source, providing meaningful functional benefit and altering the course of disease.
While we acknowledge the risk and potential of ANNX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ANNX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Data Center Stocks to Buy for the Long Term and 5 Stocks with Double Digit Returns.
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center